Botulinum Toxin in Facial Paralysis: A Neuroaesthetic Framework for Functional, Therapeutic, and Aesthetic Correction

September 2026 | Volume 25 | Issue 9 | 800 | Copyright © September 2026


Published online August 31, 2026

Roxane Scemla MDa, Hayes B. Gladstone MDb

aBiostation, Kihei, HI
bGladstone Clinic, Danville, CA

Abstract
Background: Facial paralysis (FP) produces functional deficits and facial asymmetry that may include neuromuscular discoordination with synkinesis, painful muscle contractions, disturbing facial spasms, and autonomic misdirection such as gustatory lacrimation. Although Botulinum toxin A (BTX-A) is widely used in dermatology for aesthetic indications, its therapeutic and functional role in facial paralysis is less commonly incorporated within a clinical unified framework.
Objective: To propose a neuroaesthetic framework that integrates functional restoration, therapeutic relief, and correction of facial asymmetry using Botulinum toxin A (BTX-A) in the management of facial paralysis.
Methods and Materials: A structured narrative review of PubMed Index literature was conducted to evaluate aesthetic and therapeutic applications of BTX-A and facial paralysis. Evidence was synthesized across domains of facial asymmetry, functional impairment, and neuromuscular dysregulation and organized into a clinically applicable neuroaesthetic framework for dermatologists and advanced clinicians to support a comprehensive approach.
Results: The reviewed literature supports BTX-A as an effective modality for reducing hyperkinesis and improving facial symmetry. Therapeutic benefit is also demonstrated for synkinesis, painful contractions, hemifacial spasms, and gustatory lacrimation. When applied using a comprehensive, integrated neuroaesthetic strategy, BTX-A enables concurrent management of functional deficits and therapeutic symptoms alongside aesthetic correction.
Conclusions: This review introduces a neuroaesthetic framework that unifies aesthetic, functional, and therapeutic applications of BTX-A in facial paralysis and emphasizes its multi-systemic complexity. With appropriate knowledge and understanding of facial nerve dysfunction, dermatologists and clinicians experienced with neuromodulators are well positioned to deliver comprehensive function-guided treatments across the spectrum of facial paralysis-related sequelae.

INTRODUCTION

Facial nerve palsy (FP) has multiple etiologies and is estimated to affect 20-30 per 100,000 individuals in the United States annually. Approximately 30% of affected patients experience long-term sequelae that do not fully resolve.¹,² These sequelae--both functional and aesthetic--can significantly impact quality of life and lead to psychosocial distress.3,4

In addition to visible asymmetry, FP may result in taste disturbances, dry eye syndrome, gustatory lacrimation, and motor deficits affecting speech and mastication. Botulinum toxin (BTX) has played an instrumental role in the advancement of multimodal management strategies for facial nerve disorders. Understanding facial nerve anatomy, pathophysiology, and postparalytic sequelae is essential prior to addressing aesthetic asymmetry or functional deficits.5 This review proposes a neuroaesthetic framework in which facial paralysis is first evaluated through etiology and functional deficits, followed by targeted neuromodulator interventions that address therapeutic symptoms and aesthetic asymmetry concurrently.

A Neuroaesthetic Framework for Facial Paralysis
Framework Overview
Facial paralysis represents a complex interaction between neurologic injury, functional impairment, compensatory motor activity, and aesthetic asymmetry. Management strategies that focus solely on visible asymmetry may overlook underlying neuromuscular and autonomic sequelae that contribute to persistent symptoms and patient distress.1-4 A neuroaesthetic framework integrates neurologic understanding with aesthetic principles to guide comprehensive and safe management of facial paralysis.